After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
CGEM belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Cullinan Therapeutics Inc is $512.25M. A total of 0.61 million shares were traded on the day, compared to an average of 455.70K shares.
In the most recent transaction, Jones Jeffrey Alan sold 4,895 shares of CGEM for 8.53 per share on Feb 25 ’25. After the transaction, the Chief Medical Officer now owns 174,164 company shares. In a previous transaction on Feb 25 ’25, AHMED NADIM sold 12,529 shares at 8.53 per share. CGEM shares that President and CEO owns now total 430,621.
Among the insiders who sold shares, Michaelson Jennifer disposed of 3,756 shares on Feb 25 ’25 at a per-share price of $8.53. This resulted in the Chief Scientific Officer holding 142,004 shares of CGEM after the transaction. In another insider transaction, SUMER JACQUELYN L sold 3,756 shares at $8.53 per share on Feb 25 ’25. Company shares held by the Chief Legal Officer now total 136,895.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, CGEM has a high of $24.76 and a low of $6.85.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. CGEM’s latest balance sheet shows that the firm has $290.47M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $11.75M in liabilities at the time. Its Book Value Per Share was $9.40, while its Total Shareholder’s Equity was $425.37M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CGEM is Buy with a score of 5.00.
